Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.7% - Here's What Happened

Semper Paratus Acquisition Corporation (NASDAQ:TVGN - Get Free Report)'s stock price was down 2.7% on Wednesday . The stock traded as low as $1.08 and last traded at $1.08. Approximately 654,915 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 5,087,844 shares. The stock had previously closed at $1.11.

Analysts Set New Price Targets

Separately, D. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Semper Paratus Acquisition in a research report on Wednesday, June 18th.

Semper Paratus Acquisition Stock Down 0.9%

The stock has a fifty day moving average of $1.23 and a 200 day moving average of $1.22.

Insider Activity at Semper Paratus Acquisition

In related news, CEO Ryan H. Saadi sold 1,438,206 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the completion of the transaction, the chief executive officer directly owned 116,814,453 shares in the company, valued at approximately $143,681,777.19. The trade was a 1.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 73.24% of the stock is owned by company insiders.

Hedge Funds Weigh In On Semper Paratus Acquisition

Several large investors have recently added to or reduced their stakes in TVGN. JPMorgan Chase & Co. raised its stake in Semper Paratus Acquisition by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after purchasing an additional 16,695 shares during the period. Barclays PLC raised its position in shares of Semper Paratus Acquisition by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after buying an additional 12,847 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Semper Paratus Acquisition in the fourth quarter worth $55,000. Nuveen LLC bought a new position in shares of Semper Paratus Acquisition during the first quarter worth $97,000. Finally, Northern Trust Corp boosted its position in shares of Semper Paratus Acquisition by 13.0% during the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares during the last quarter.

Semper Paratus Acquisition Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.